Bruker (BSP:B2RK34) Cyclically Adjusted Revenue per Share: R$9.72 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:B2RK34 Bruker Corp BSP:B2RK34
57 GF Score
Price R$30.50
GF Value R$30.28
Valuation Fairly Valued
! 11 Warning Signs
View Full Analysis

What is Bruker Cyclically Adjusted Revenue per Share?

Bruker BSP:B2RK34 57 Cyclically Adjusted Revenue per Share is R$9.72 as of Jun. 2026. GuruFocus rates BSP:B2RK34 with a GF Score™ of 57/100 and a GF Value™ of R$30.28 (Fairly Valued). The stock has 11 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bruker's adjusted revenue per share for the three months ended in Jun. 2026 was R$28.211. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$9.72 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Bruker's average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bruker was 14.10% per year. The lowest was 5.90% per year. And the median was 8.00% per year.

As of today (2026-08-31), Bruker's current stock price is R$30.50. Bruker's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was R$9.72. Bruker's Cyclically Adjusted PS Ratio of today is 3.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bruker was 7.22. The lowest was 1.74. And the median was 3.64.


Bruker  (BSP:B2RK34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bruker's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=30.50/9.72
=3.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bruker was 7.22. The lowest was 1.74. And the median was 3.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bruker Cyclically Adjusted Revenue per Share Related Terms


Bruker Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bruker's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bruker Cyclically Adjusted Revenue per Share Chart

Bruker Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bruker Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 9.72

BSP:B2RK34 vs PODD, BIO, GKOS: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Bruker's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bruker Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bruker's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bruker's Cyclically Adjusted PS Ratio falls into.


BSP:B2RK34
57GF Score
Bruker Corp BSP:B2RK34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bruker Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bruker's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=28.211/333.9520*333.9520
=28.211

Current CPI (Jun. 2026) = 333.9520.

Bruker Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 7.935 241.428 10.976
201612 9.816 241.432 13.578
201703 7.500 243.801 10.273
201706 8.524 244.955 11.621
201709 8.598 246.819 11.633
201712 11.155 246.524 15.111
201803 9.016 249.554 12.065
201806 10.657 251.989 14.123
201809 12.180 252.439 16.113
201812 13.676 251.233 18.179
201903 11.223 254.202 14.744
201906 11.993 256.143 15.636
201909 13.796 256.759 17.944
201912 15.845 256.974 20.591
202003 13.332 258.115 17.249
202006 14.240 257.797 18.447
202009 17.897 260.280 22.963
202012 20.963 260.474 26.877
202103 20.403 264.877 25.724
202106 18.772 271.696 23.073
202109 21.037 274.310 25.611
202112 25.328 278.802 30.338
202203 19.557 287.504 22.717
202206 19.827 296.311 22.346
202209 22.545 296.808 25.366
202212 25.124 296.797 28.269
202303 24.183 301.836 26.756
202306 22.409 305.109 24.527
202309 24.905 307.789 27.022
202312 28.618 306.746 31.156
202403 24.633 312.332 26.338
202406 29.140 314.175 30.974
202409 31.493 315.301 33.356
202412 39.345 315.605 41.632
202503 30.379 319.799 31.723
202506 29.151 322.561 30.180
202509 30.401 324.800 31.258
202512 35.051 324.054 36.122
202603 28.199 330.213 28.518
202606 28.211 333.952 28.211

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$9.72 mean?
Bruker (BSP:B2RK34) has a Cyclically Adjusted Revenue per Share of R$9.72 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bruker and its competitors.
Is Bruker's Cyclically Adjusted Revenue per Share too high?
Bruker's current Cyclically Adjusted Revenue per Share is R$9.72. Overall, Bruker has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bruker's Cyclically Adjusted Revenue per Share compare to PODD and BIO?
Bruker's Cyclically Adjusted Revenue per Share of R$9.72 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bruker and its competitors. Bruker's current Cyclically Adjusted Revenue per Share is R$9.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bruker stock overvalued right now?
Based on GuruFocus' analysis, Bruker (BSP:B2RK34) is currently considered Fairly Valued. The stock's GF Value™ is R$30.28, compared to a current price of R$30.50 — trading 0.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$9.72. Bruker's overall GF Score™ is 57/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bruker (BSP:B2RK34), the current Cyclically Adjusted Revenue per Share is R$9.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bruker (BSP:B2RK34) Overvalued in 2026?

Based on GuruFocus' analysis, Bruker stock appears to be overvalued. The current stock price of R$30.50 is trading 0.7% above its estimated GF Value™ of R$30.28. GuruFocus considers Bruker to be Fairly Valued.

Key valuation signals for BSP:B2RK34:

  • Cyclically Adjusted Revenue per Share: R$9.72
  • GF Value™: R$30.28 vs. price of R$30.50 (0.7% above fair value)
  • GF Score™: 57/100 with 11 warning signs

No single metric tells the full story. See the BSP:B2RK34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bruker Business Description

Address 40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
57GF Score

Get the complete analysis for BSP:B2RK34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$30.50
Price
R$30.28
GF Value